Company Profile · MedTech · Neuro-Oncology
GT Medical Technologies
The Arizona company putting radiation inside the brain - the moment the tumor comes out.
Tempe, Arizona · Founded 2017 · ~120 employees
The Arizona company putting radiation inside the brain - the moment the tumor comes out.
Tempe, Arizona · Founded 2017 · ~120 employees
GT Medical Technologies makes one thing exceptionally well: GammaTile, an FDA-cleared, bioresorbable radiation implant for operable brain tumors. During surgery to remove a tumor, the neurosurgeon lines the resection cavity with soft collagen tiles embedded with Cesium-131 radioactive seeds. Radiation begins immediately - at the moment residual tumor cell counts are lowest - and stays focused on the tumor bed while sparing healthy brain tissue. Then the tile dissolves. No second procedure to remove it.
The approach is called surgically targeted radiation therapy, and it rearranges the usual timeline of cancer care. Conventional treatment asks a patient to heal from surgery and then return, weeks later, for external beam radiation - time in which stray cancer cells can regroup. GammaTile compresses that gap to zero.
The company that built it did not set out to be a company at all. In 2011, five brain tumor specialists at the Barrow Neurological Institute in Phoenix kept seeing the same heartbreak: patients whose recurrent tumors were operable, but who had already received all the external radiation their healthy tissue could safely absorb. The clinicians asked whether radiation delivered from inside the cavity could give those patients another chance. Six years later, in October 2017, they incorporated GT Medical Technologies to carry the idea through FDA clearance.
This financing is validation of GammaTile's potential to be a standard of care treatment for operable brain tumors.Per Langoe, Chief Executive Officer
In 2026, GT Medical released final data from ROADS, a randomized controlled trial comparing GammaTile with standard care in patients with operable brain metastases. The numbers are what turned a clinician's idea into an investment thesis - and what led a new lead investor to oversubscribe the company's Series E.
* Figures per GT Medical Technologies' reported ROADS RCT results, 2026. Bar lengths are illustrative.
Bioresorbable collagen tiles with Cesium-131 seeds, implanted at the time of resection. Cleared by the FDA in 2018 for recurrent brain tumors and in 2020 for newly diagnosed malignant tumors.
A designation recognizing hospitals with proven GammaTile expertise and multidisciplinary neuro-oncology care. The USC Brain Tumor Center was the first designee.
A newly initiated randomized controlled trial testing GammaTile in patients with newly diagnosed glioblastoma - one of the hardest brain cancers to treat.
GT Medical sells to neurosurgeons, radiation oncologists, and brain tumor centers across academic and community hospitals in the United States. The patients on the receiving end are adults with newly diagnosed or recurrent operable brain tumors, including brain metastases and glioblastoma. More than 2,000 have been treated to date.
It is a medical device manufacturer: GammaTile generates revenue per implant procedure, and growth is driven by clinical adoption, reimbursement, physician training, and Centers of Excellence designations. Venture equity funds the commercial scale-up. Estimated annual revenue is roughly $43.9M.
The market for brain tumor radiation is built around big machines and repeat visits - external beam radiation and stereotactic radiosurgery systems like Elekta's Gamma Knife and Accuray's CyberKnife, plus tumor-treating fields from Novocure. Those approaches bring the patient to the radiation.
GT Medical inverts it. GammaTile is placed once, inside a surgery that is already happening, and delivers its dose from within the tumor bed. The differentiators are timing (radiation starts the day of surgery), focus (dose concentrated at the cavity), and convenience (a bioresorbable device that needs no removal).
We are excited to lead this financing and to work with GT to unlock the potential of GammaTile therapy.Jason Rostovsky, Viking Global Investors
That distinct position is what the 2026 Series E is meant to press - moving GammaTile from a therapy adopted by leading centers toward a broadly accepted standard of care.
CEO Per Langoe joined in 2024 after co-founding and leading Palette Life Sciences, bringing more than two decades of radiation-oncology commercialization experience to a company moving from clinical adoption to commercial scale.
Five brain tumor specialists conceive GammaTile for recurrent tumors that could no longer receive external radiation.
The founders formally launch the company in October with the goal of getting GammaTile FDA-cleared.
GammaTile is cleared for recurrent brain tumors.
Clearance extends to newly diagnosed malignant tumors; full US market launch begins in March.
A veteran life sciences leader joins to drive commercial adoption and the next phase of growth.
GammaTile reaches 2,000 patients treated and launches its Centers of Excellence program with USC.
After ROADS shows superiority over standard care, the company closes an oversubscribed $100M round led by Viking Global.
Oversubscribed, led by Viking Global Investors, with MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures.
Final close of an oversubscribed round ($37M initial) to advance commercial treatment for patients with operable brain tumors.
Cleared in 2018 for recurrent tumors and 2020 for newly diagnosed malignant tumors - the regulatory foundation for everything since.
An FDA-cleared, bioresorbable collagen tile embedded with Cesium-131 radioactive seeds. Surgeons implant it in the tumor cavity during resection to deliver immediate, focused radiation to residual tumor cells while sparing healthy brain tissue.
Five brain tumor specialists from Barrow Neurological Institute: David G. Brachman, Heyoung McBride, Peter Nakaji, Emad Youssef (deceased), and Theresa Thomas. The company was formally incorporated in October 2017.
Roughly $246 million in total, including a $53 million Series D and an oversubscribed $100 million Series E in June 2026 led by Viking Global Investors.
In the ROADS randomized controlled trial, GammaTile reduced 12-month surgical-bed recurrence to 1.3% versus 15.4% for standard care, with 24-month overall survival of 61.7% versus 35.7%.
Headquartered in Tempe, Arizona, with approximately 120 employees. GammaTile is used by cancer centers across the United States.